Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/35917
Title: | Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial | Authors: | Wauters, Lucas SLAETS, Leen De Paepe, Kim Ceulemans, Matthias WETZELS, Suzan Geboers, Karlien Toth, Joran Thys, Wannes Dybajlo, Raf Walgraeve, Daan Biessen, Erik Verbeke, Kristin Tack, Jan Wiele, Tom Van de HELLINGS, Niels Vanuytsel, Tim |
Issue Date: | 2021 | Publisher: | ELSEVIER INC | Source: | LANCET GASTROENTEROLOGY & HEPATOLOGY, 6 (10) , p. 784 -792 | Abstract: | Background Current treatments for functional dyspepsia have limited efficacy or present safety issues. We aimed to assess spore-forming probiotics in functional dyspepsia as monotherapy or add-on therapy to long-term treatment with proton-pump inhibitors. Methods In this single-centre, randomised, double-blind, placebo-controlled pilot trial that took place at University Hospitals Leuven (Leuven, Belgium), adult patients (>= 18 years) with functional dyspepsia (as defined by Rome IV criteria, on proton-pump inhibitors or off proton-pump inhibitors) were randomly assigned (1:1) via computergenerated blocked lists, stratified by proton-pump inhibitor status, to receive 8 weeks of treatment with probiotics (Bacillus coagulans MY01 and Bacillus subtilis MY02, 2.5 x 10. colony-forming units per capsule) or placebo consumed twice per day, followed by an open-label extension phase of 8 weeks. Individuals with a history of abdominal surgery, diabetes, coeliac or inflammatory bowel disease, active psychiatric conditions, and use of immunosuppressant drugs, antibiotics, or probiotics in the past 3 months were excluded. All patients and on-site study personnel were masked to treatment allocation in the first 8 weeks. Symptoms, immune activation, and faecal microbiota were assessed and recorded. The primary endpoint was a decrease of at least 0.7 in the postprandial distress syndrome (PDS) score of the Leuven Postprandial Distress Scale in patients with a baseline PDS score of 1 or greater (at least mild symptoms), assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT04030780. Findings Between June 3, 2019, and March 11, 2020, of 93 individuals assessed for eligibility, we included 68 patients with functional dyspepsia (51 [75%] women, mean age 40.1 years [SD 14.4], 34 [50%] on proton-pump inhibitors). We randomly assigned 32 participants to probiotics and 36 to placebo. The proportion of clinical responders was higher with probiotics (12 [48%] of 25) than placebo (six [20%] of 30; relative risk 1.95 [95% CI 1.07-4.11]; p=0.028). The number of patients with adverse events was similar with probiotics (five [16%] of 32) and placebo (12 [33%] of 36). Two serious adverse events occurring during the open-label phase (appendicitis and syncope in two separate patients) were assessed as unlikely to be related to the study product. Interpretation In this exploratory study, B coagulans MY01 and B subtilis MY02 were efficacious and safe in the treatment of functional dyspepsia. Participants had potentially beneficial immune and microbial changes, which could provide insights into possible underlying mechanisms as future predictors or treatment targets. | Notes: | Vanuytsel, T (corresponding author), Univ Hosp Leuven, Dept Gastroenterol & Hepatol, B-3000 Leuven, Belgium. tim.vanuytsel@uzleuven.be |
Keywords: | Adult;Bacillus coagulans;Bacillus subtilis;Belgium;Case-Control Studies;Dietary Supplements;Double-Blind Method;Dyspepsia;Female;Humans;Male;Middle Aged;Pilot Projects;Placebos;Prevalence;Probiotics;Proton Pump Inhibitors;Safety;Spores;Treatment Outcome | Document URI: | http://hdl.handle.net/1942/35917 | e-ISSN: | 2468-1253 | DOI: | 10.1016/S2468-1253(21)00226-0 | ISI #: | WOS:000706515900010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Show full item record
WEB OF SCIENCETM
Citations
52
checked on Oct 12, 2024
Page view(s)
38
checked on Jul 15, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.